Decide what better performance means
A heavier lift, a faster race, and less soreness are different goals. If they are grouped under one word such as performance, a modest finding in one area can be made to sound like proof of all three.
Before considering a treatment, define the outcome that matters to you and how it would be measured consistently. A training log may help describe a concern, but a before-and-after personal record cannot isolate the effect of a drug when training, sleep, nutrition, and expectations change at the same time.
The strongest evidence would compare relevant groups under controlled conditions and report both benefit and adverse effects. An explanation of hormone biology is the beginning of that investigation, not its conclusion.
Consistency matters when following progress. Changing the test, equipment, training phase, or definition of success can make a result difficult to interpret. If the original goal was a stronger lift, an improved body-composition estimate should not quietly replace it as the reason to continue treatment. Agreeing on the outcome in advance makes the later conversation more honest, whether the result is encouraging, unchanged, or uncertain.
A frequently relevant trial tested growth hormone
A 2010 randomized trial in 96 recreational athletes tested growth hormone, with additional testosterone groups among men. It did not test sermorelin. The investigators measured several performance outcomes rather than treating body composition as a complete answer.
Sprint capacity improved in the growth hormone comparison, while other performance measures did not significantly improve. Increased lean mass included an increase in extracellular water. The authors also noted uncertainty about the athletic importance of the sprint finding and the study’s ability to establish safety.
These results should not become a sermorelin performance percentage. They are useful because they show why a claim about lean mass, strength, or athletic benefit must identify both the intervention and the particular outcome.
Lean mass is not the same as useful muscle function
A body-composition report divides tissue into measurement categories. A change in a category is not automatically equivalent to more contractile muscle, better coordination, or improved performance in your sport.
Ask how the study measured body composition and whether it also measured strength or function. If the only reported improvement is a scan result, the clinical conclusion should remain limited to that measurement.
Small sermorelin-related studies in older adults also need to be read in their own context. Their participants and goals differ from those of younger trained athletes. Our muscle and recovery article discusses that evidence separately, without treating it as a training protocol.
Recovery and injury prevention need their own trials
A claim about recovering from workouts should specify what changed: pain, time to resume activity, repeat performance, or another outcome. Feeling less tired after a session is not evidence that a tendon healed faster or an injury risk fell.
For injury claims, ask whether the study actually involved the same injury, whether the treatment was sermorelin, and whether return to activity was assessed meaningfully. An animal experiment or tissue-culture result may inform research but cannot establish a reliable recovery timeline for an athlete.
New pain or declining exercise tolerance also deserves a clinical assessment on its own terms. A hormone-focused consultation should not bypass the possibility that training load, an injury, or another health problem needs attention.
Keep the sporting rules separate from the benefit claim
For athletes subject to anti-doping rules, eligibility is an additional consideration. WADA lists sermorelin among prohibited growth hormone-releasing factors. A prescription or a claim that a peptide is natural does not resolve the sporting rules.
Read our anti-doping guide and contact the relevant sporting authority before a proposed treatment. Do not interpret a prohibition as proof that a drug will improve your own performance; regulatory classification and clinical efficacy are different questions.
At the appointment, ask for evidence tied to the outcome you named at the start. If a provider cannot identify that evidence, the uncertainty belongs in the decision rather than being replaced by a general promise of better workouts.
Sources & further reading
Sources reviewed October 2026. Provider prices and terms may change.